OTC Claritin Access Needs Study Before Other Switches Are Forced – Pfizer
This article was originally published in The Tan Sheet
Executive Summary
FDA should evaluate whether OTC Claritin has increased access and lowered costs for allergy sufferers before deciding whether to require the other second-generation antihistamines to switch OTC, Pfizer asserts in May 7 comments to the agency